Compare APOG & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APOG | JANX |
|---|---|---|
| Founded | 1949 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.6M | 840.4M |
| IPO Year | 1994 | 2021 |
| Metric | APOG | JANX |
|---|---|---|
| Price | $39.02 | $16.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $47.00 | $47.00 |
| AVG Volume (30 Days) | 340.6K | ★ 1.4M |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,404,733,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.07 | N/A |
| P/E Ratio | $73.69 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $30.75 | $12.12 |
| 52 Week High | $50.88 | $35.34 |
| Indicator | APOG | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 67.35 |
| Support Level | $36.90 | $13.00 |
| Resistance Level | $39.06 | $16.60 |
| Average True Range (ATR) | 2.44 | 0.70 |
| MACD | -0.49 | 0.18 |
| Stochastic Oscillator | 1.16 | 97.71 |
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.